A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease

Neurology

Volumn 78, Issue 16, 2012, Pages 1229-1236

  Richard, I H ^a   McDermott, M P ^a   Kurlan, R ^a,b   Lyness, J M ^a   Como, P G ^a   Pearson, N ^a   Factor, S A ^c   Juncos, J ^c   Ramos, C Serrano ^d   Brodsky, M ^e   Manning, C ^f   Marsh, L ^g   Shulman, L ^h   Fernandez, H H ⁱ   Black, K J ^j   Panisset, M ^k   Christine, C W ^l   Jiang, W ^m   Singer, C ⁿ   Horn, S ^o   Pfeiffer, R ^p   Rottenberg, D ^q   Slevin, J ^r   Elmer, L ^s   Press, D ^t   Hyson, H C ^u   McDonald, W ^c   more..

^a UNIVERSITY OF ROCHESTER   (United States)

^b Atlantic Neuroscience Institute   (United States)

^c EMORY UNIVERSITY   (United States)

^d UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f UNIVERSITY OF VIRGINIA   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h UNIVERSITY OF MARYLAND   (United States)

ⁱ UNIVERSITY OF FLORIDA   (United States)

^j WASHINGTON UNIVERSITY   (United States)

^k CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m DUKE UNIVERSITY   (United States)

ⁿ UNIVERSITY OF MIAMI   (United States)

^o UNIVERSITY OF PENNSYLVANIA   (United States)

^p UNIVERSITY OF TENNESSEE   (United States)

^q UNIVERSITY OF MINNESOTA   (United States)

^r UNIVERSITY OF KENTUCKY   (United States)

^s MEDICAL COLLEGE OF OHIO   (United States)

^t BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^u LONDON HEALTH SCIENCES CENTRE   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PAROXETINE; PLACEBO; VENLAFAXINE;

ANXIETY DISORDER; ARTICLE; BALANCE DISORDER; CONCENTRATION LOSS; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DIAPHORESIS; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DREAMING; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DSM-IV; DYSKINESIA; FATIGUE; FOLLOW UP; HAMILTON SCALE; HEADACHE; HEART ARRHYTHMIA; HEARTBURN; HUMAN; HYPERTENSION; INSOMNIA; LETHARGY; MAJOR CLINICAL STUDY; MICTURITION DISORDER; MOTOR PERFORMANCE; MULTICENTER STUDY; NAUSEA; PANIC; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTLESS LEGS SYNDROME; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; THERAPY EFFECT; TREMOR;

EID: 84860785589     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182516244     Document Type: Article

References (36)

1. Liu C-Y, Wang S-J, Fuh J-L, Lin C-H, Yang Y-Y, Liu H-C. The correlation of depression with functional activity in Parkinson's disease. J Neurol 1997;244:493-498. (Pubitemid 27424787)
2. Kuopio A, Marttila R, Hellenius H, Toivonen M, Rinne U. The quality of life in Parkinson's disease. Mov Disord 2000;15:216-223. (Pubitemid 30166726)
3. Phillips P. Keeping depression at bay helps patients with Parkinson's disease. JAMA 1999;282:1118-1119. (Pubitemid 29441947)
4. The Global Parkinson's Disease Survey (GPDS) Steering Committee. Factors impacting on quality of life in Parkinson's disease: Results from an international survey. Mov Disord 2001;17:60-67.
5. Menza M, Dobkin RD, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009;72:886-892.
6. Devos D, Dujardin K, Poirot I, et al. Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: A double-blind, randomized, placebo-controlled study. Mov Disord 2008;23:850-857.
7. Yeragani VK, Roose S, Mallavarapu M, Radhakrishna RK, Pesce V. Major depression with ischemic heart disease: Effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate. Neuropsychobiology 2002;46:125-135.
8. Yeragani VK, Pesce V, Jayaraman A, Roose S. Major depression with ischemic heart disease: Effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biol Psychiatry 2002;52:418-429. (Pubitemid 35266733)
9. Nelson J, Kennedy J, Pollock B, et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. Am J Psychiatry 1999;156: 1024-1028. (Pubitemid 29302794)
10. Salzman C. Pharmacologic treatment of depression in the elderly. J Clin Psychiatry 1993;54:23-28. (Pubitemid 23081706)
11. Altamura AC, DeNovelis F, Guercetti G. Fluoxetine compared with amitriptyline in elderly depression: A controlled clinical trial. Int J Clin Pharmacol Res 1989;9:391-396. (Pubitemid 20230499)
12. Feighner J, Boyer W, Meredith C. An overview of fluoxetine in geriatric depression. Br J Psychiatry 1988;153: 105-108.
13. Cohn C, Shrivastava R, Mendels J. Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients. J Clin Psychiatry 1990;5:28-33.
14. Dunner D, Cohn J, Walshe TI. Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression. J Clin Psychiatry 1992;53:57-60.
15. Guillibert E, Pelicier Y, Archambault J, Chabannes J, Clerc G, Desvilles M. A double-blind, multicentre study of paroxetine versus clomipramine in depressed elderly patients. Acta Psychiatr Scand 1989;80:132-134. (Pubitemid 19236659)
16. Simons J. Fluoxetine in Parkinson's disease. Mov Disord 1996;11:581-582. (Pubitemid 26306088)
17. Jansen Steur H. Increase of Parkinson disability after fluoxetine medication. Neurology 1993;43:211-213.
18. Jimenez-Jimenez F, Tejeiro J, Martinez-Junquera, et al. Parkinsonism exacerbated by paroxetine. Neurology 1994; 44:2406. (Pubitemid 24382750)
19. Dubovsky S. Geriatric neuropsychopharmacology. In: Coffey C, Cummings J, eds. Textbook of Geriatric Neuropsychiatry. Washington, DC: American Psychiatric Press; 1994: 595-631.
20. Hirschfeld R. Efficacy of SSRIs and newer antidepressants in severe depression: Comparison with TCAs. J Clin Psychiatry 1999;60:326-335. (Pubitemid 29246899)
21. Entsuah A, Huang H, Thase M. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine's elective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry 2001;62: 869-877. (Pubitemid 33131173)
22. Benedictis E. Double-blind comparison of venlafaxine and amitriptyline in outpatients with major depression with or without melancholia. J Psychopharmacol 2000;14:61-66. (Pubitemid 30156540)
23. Applebaum PS, Grisso T. MacCAT-CR: MacArthur Competence Assessment Tool for Clinical Research. Sarasota, FL: Professional Resource Press; 2001.
24. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. Washington, DC: American Psychiatric Association; 1994.
25. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
26. Montgomery S, Asberg M. New depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382.
27. Beck AT, Steer RAB, R., Ranieri W. Comparison of Beck Depression Inventories IA and II in psychiatric outpatients. J Pers Assess 1996;67:588-597. (Pubitemid 26382973)
28. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: A preliminary report. J Psychiatry Res 1983;17:37-49. (Pubitemid 13123113)
29. Conners C, Barkley R. Rating scales and checklists for psychopharmacologic trials. Psychopharmacol Bull 1985;21: 809-854.
30. Fahn S, Elton RL. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent Developments in Parkinson's Disease. Florham Park, NJ: MacMillan Healthcare Information; 1992: 153-163.
31. Uc EY, McDermott MP, Marder KS, et al. Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort. Neurology 2009;73: 1469-1477.
32. Little RJA, Rubin DB. Statistical Analysis with Missing Data, Second Edition. Hoboken: John Wiley and Sons; 2002.
33. Okun MS, Fernandez HH. Will tricyclic antidepressants make a comeback for depressed Parkinson disease patients. Neurology 2009;72:868-869.
34. Brunoni AR, Lopes M, Kaptchuk TJ, Fregni F. Placebo response of non-pharmacological and pharmacological trials in major depression: A systematic review and metaanalysis. PLoS One 2009;4.
35. Senn S, Julious S. Measurements in clinical trials: A neglected issue for statisticians? Stat Med 2009;28:3189-3209.
36. Barone P, Poewe WA, S., Debieuvre C, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: A randomised, double-blind, placebocontrolled trial. Lancet Neurol 2010;9:573-580.